111 related articles for article (PubMed ID: 23609829)
1. Phase I dose-escalating study of TAS-106 in combination with carboplatin in patients with solid tumors.
Naing A; Fu S; Zinner RG; Wheler JJ; Hong DS; Arakawa K; Falchook GS; Kurzrock R
Invest New Drugs; 2014 Feb; 32(1):154-9. PubMed ID: 23609829
[TBL] [Abstract][Full Text] [Related]
2. Phase I and pharmacokinetic study of 3'-C-ethynylcytidine (TAS-106), an inhibitor of RNA polymerase I, II and III,in patients with advanced solid malignancies.
Hammond-Thelin LA; Thomas MB; Iwasaki M; Abbruzzese JL; Lassere Y; Meyers CA; Hoff P; de Bono J; Norris J; Matsushita H; Mita A; Rowinsky EK
Invest New Drugs; 2012 Feb; 30(1):316-26. PubMed ID: 20839029
[TBL] [Abstract][Full Text] [Related]
3. Phase I study of second-line chemotherapy with docetaxel and carboplatin in advanced non-small-cell lung cancer.
Oka M; Fukuda M; Nagashima S; Fukuda M; Kinoshita A; Soda H; Doi S; Narasaki F; Suenaga M; Takatani H; Nakamura Y; Kawabata S; Tsurutani J; Kanda T; Kohno S
Cancer Chemother Pharmacol; 2001 Dec; 48(6):446-50. PubMed ID: 11800024
[TBL] [Abstract][Full Text] [Related]
4. Phase I study of oral ridaforolimus in combination with paclitaxel and carboplatin in patients with solid tumor cancers.
Chon HS; Kang S; Lee JK; Apte SM; Shahzad MM; Williams-Elson I; Wenham RM
BMC Cancer; 2017 Jun; 17(1):407. PubMed ID: 28595616
[TBL] [Abstract][Full Text] [Related]
5. A phase I study evaluating the safety and pharmacokinetics of weekly paclitaxel and carboplatin in relapsed ovarian cancer.
Leiser AL; Maluf FC; Chi DS; Sabbatini P; Hensley ML; Schwartz L; Venkatraman E; Spriggs D; Aghajanian C
Int J Gynecol Cancer; 2007; 17(2):379-86. PubMed ID: 17362316
[TBL] [Abstract][Full Text] [Related]
6. Parallel phase Ib studies of two schedules of buparlisib (BKM120) plus carboplatin and paclitaxel (q21 days or q28 days) for patients with advanced solid tumors.
Hyman DM; Snyder AE; Carvajal RD; Gerecitano JF; Voss MH; Ho AL; Konner J; Winkelmann JL; Stasi MA; Monson KR; Iasonos A; Spriggs DR; Bialer P; Lacouture ME; Teitcher JB; Katabi N; Fury MG
Cancer Chemother Pharmacol; 2015 Apr; 75(4):747-55. PubMed ID: 25672916
[TBL] [Abstract][Full Text] [Related]
7. Phase I dose-finding and pharmacokinetic study of paclitaxel and carboplatin with oral valspodar in patients with advanced solid tumors.
Patnaik A; Warner E; Michael M; Egorin MJ; Moore MJ; Siu LL; Fracasso PM; Rivkin S; Kerr I; Litchman M; Oza AM
J Clin Oncol; 2000 Nov; 18(21):3677-89. PubMed ID: 11054441
[TBL] [Abstract][Full Text] [Related]
8. Phase I pharmacokinetic and pharmacodynamic study of Carboplatin and topotecan administered intravenously every 28 days to patients with malignant solid tumors.
Boss DS; Siegel-Lakhai WS; van Egmond-Schoemaker NE; Pluim D; Rosing H; Ten Bokkel Huinink WW; Beijnen JH; Schellens JH
Clin Cancer Res; 2009 Jul; 15(13):4475-83. PubMed ID: 19531625
[TBL] [Abstract][Full Text] [Related]
9. Phase I and pharmacokinetic trial of carboplatin and albumin-bound paclitaxel, ABI-007 (Abraxane) on three treatment schedules in patients with solid tumors.
Stinchcombe TE; Socinski MA; Walko CM; O'Neil BH; Collichio FA; Ivanova A; Mu H; Hawkins MJ; Goldberg RM; Lindley C; Dees EC
Cancer Chemother Pharmacol; 2007 Oct; 60(5):759-66. PubMed ID: 17285317
[TBL] [Abstract][Full Text] [Related]
10. Plasma and cerebrospinal fluid pharmacokinetics of topotecan in a phase I trial of topotecan, tamoxifen, and carboplatin, in the treatment of recurrent or refractory brain or spinal cord tumors.
Morgan RJ; Synold T; Mamelak A; Lim D; Al-Kadhimi Z; Twardowski P; Leong L; Chow W; Margolin K; Shibata S; Somlo G; Yen Y; Frankel P; Doroshow JH
Cancer Chemother Pharmacol; 2010 Oct; 66(5):927-33. PubMed ID: 20107803
[TBL] [Abstract][Full Text] [Related]
11. A phase I trial of oral administration of panobinostat in combination with paclitaxel and carboplatin in patients with solid tumors.
Jones SF; Infante JR; Thompson DS; Mohyuddin A; Bendell JC; Yardley DA; Burris HA
Cancer Chemother Pharmacol; 2012 Sep; 70(3):471-5. PubMed ID: 22851205
[TBL] [Abstract][Full Text] [Related]
12. A phase I study with an expanded cohort to assess the feasibility of intravenous paclitaxel, intraperitoneal carboplatin and intraperitoneal paclitaxel in patients with untreated ovarian, fallopian tube or primary peritoneal carcinoma: a Gynecologic Oncology Group study.
Gould N; Sill MW; Mannel RS; Thaker PH; Disilvestro P; Waggoner S; Yamada SD; Armstrong DK; Wenzel L; Huang H; Fracasso PM; Walker JL
Gynecol Oncol; 2012 Apr; 125(1):54-8. PubMed ID: 22155262
[TBL] [Abstract][Full Text] [Related]
13. Phase I and pharmacologic study of sequential topotecan-carboplatin-etoposide in patients with extensive stage small cell lung cancer.
Miller AA; Al Omari A; Murry DJ; Case D
Lung Cancer; 2006 Dec; 54(3):379-85. PubMed ID: 17049403
[TBL] [Abstract][Full Text] [Related]
14. Phase 1 study of veliparib (ABT-888), a poly (ADP-ribose) polymerase inhibitor, with carboplatin and paclitaxel in advanced solid malignancies.
Appleman LJ; Beumer JH; Jiang Y; Lin Y; Ding F; Puhalla S; Swartz L; Owonikoko TK; Donald Harvey R; Stoller R; Petro DP; Tawbi HA; Argiris A; Strychor S; Pouquet M; Kiesel B; Chen AP; Gandara D; Belani CP; Chu E; Ramalingam SS
Cancer Chemother Pharmacol; 2019 Dec; 84(6):1289-1301. PubMed ID: 31549216
[TBL] [Abstract][Full Text] [Related]
15. A phase I pharmacokinetic and safety study of Paclitaxel Injection Concentrate for Nano-dispersion (PICN) alone and in combination with carboplatin in patients with advanced solid malignancies and biliary tract cancers.
Ma WW; Zhu M; Lam ET; Diamond JR; Dy GK; Fisher GA; Goff LW; Alberts S; Bui LA; Sanghal A; Kothekar M; Khopade A; Chimote G; Faulkner R; Eckhardt SG; Adjei AA; Jimeno A
Cancer Chemother Pharmacol; 2021 Jun; 87(6):779-788. PubMed ID: 33634324
[TBL] [Abstract][Full Text] [Related]
16. Phase I study of weekly plitidepsin as 1-hour infusion combined with carboplatin in patients with advanced solid tumors or lymphomas.
Salazar R; Plummer R; Oaknin A; Robinson A; Pardo B; Soto-Matos A; Yovine A; Szyldergemajn S; Calvert AH
Invest New Drugs; 2011 Dec; 29(6):1406-13. PubMed ID: 20623160
[TBL] [Abstract][Full Text] [Related]
17. A phase I study of lapatinib in combination with carboplatin in women with platinum sensitive recurrent ovarian carcinoma.
Kimball KJ; Numnum TM; Kirby TO; Zamboni WC; Estes JM; Barnes MN; Matei DE; Koch KM; Alvarez RD
Gynecol Oncol; 2008 Oct; 111(1):95-101. PubMed ID: 18692224
[TBL] [Abstract][Full Text] [Related]
18. A phase I and pharmacokinetic study of indisulam in combination with carboplatin.
Dittrich C; Zandvliet AS; Gneist M; Huitema AD; King AA; Wanders J
Br J Cancer; 2007 Feb; 96(4):559-66. PubMed ID: 17285128
[TBL] [Abstract][Full Text] [Related]
19. Phase I and pharmacologic study of the combination paclitaxel and carboplatin as first-line chemotherapy in stage III and IV ovarian cancer.
Huizing MT; van Warmerdam LJ; Rosing H; Schaefers MC; Lai A; Helmerhorst TJ; Veenhof CH; Birkhofer MJ; Rodenhuis S; Beijnen JH; ten Bokkel Huinink WW
J Clin Oncol; 1997 May; 15(5):1953-64. PubMed ID: 9164207
[TBL] [Abstract][Full Text] [Related]
20. A phase 1 study of KOS-862 (Epothilone D) co-administered with carboplatin (Paraplatin®) in patients with advanced solid tumors.
Monk JP; Villalona-Calero M; Larkin J; Otterson G; Spriggs DS; Hannah AL; Cropp GF; Johnson RG; Hensley ML
Invest New Drugs; 2012 Aug; 30(4):1676-83. PubMed ID: 21826439
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
